Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

See Remarks

Chief Financial Officer

Principal Accounting Officer

Chief Medical Officer

Chief Executive Officer

SVP, GC & CCO

PRINCIPAL ACCOUNTING OFFICER

EVP, CHIEF MEDICAL OFFICER

CHIEF EXECUTIVE OFFICER

SVP, Chief Medical Officer

Chief Scientific Officer

President and CFO

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 which is in phase I clinical trial for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver a...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-05	Premium	sold	Premium	Premium	Premium	-
2024-04-05	Premium	acquired	Premium	Premium	Premium	-
2024-04-05	Premium	acquired	Premium	Premium	Premium	-
2024-04-05	Premium	back to issuer	Premium	Premium	Premium	-
2024-04-05	Premium	sold	Premium	Premium	Premium	See Remarks
2024-04-05	Premium	back to issuer	Premium	Premium	Premium	-
2024-04-05	Premium	back to issuer	Premium	Premium	Premium	-
2024-04-05	Premium	back to issuer	Premium	Premium	Premium	-
2024-04-05	Premium	back to issuer	Premium	Premium	Premium	-
2024-04-05	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-04-05	Premium	acquired	Premium	Premium	Premium	-
2024-04-05	Premium	back to issuer	Premium	Premium	Premium	-
2024-04-05	Premium	back to issuer	Premium	Premium	Premium	-
2024-04-05	Premium	back to issuer	Premium	Premium	Premium	-
2024-04-05	Premium	sold	Premium	Premium	Premium	Principal Accounting Officer
2024-04-05	Premium	sold	Premium	Premium	Premium	-
2024-04-05	Premium	sold	Premium	Premium	Premium	-
2024-04-05	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-04-05	Premium	back to issuer	Premium	Premium	Premium	-
2024-04-05	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-04-05	Premium	back to issuer	Premium	Premium	Premium	-
2024-04-05	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-04-05	Premium	acquired	Premium	Premium	Premium	-
2024-04-05	Premium	back to issuer	Premium	Premium	Premium	-
2024-04-05	Premium	back to issuer	Premium	Premium	Premium	-

NGM - NGM Biopharmaceuticals Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for NGM